DECREASE IN PULMONARY-FUNCTION DURING BLEOMYCIN-CONTAINING COMBINATION CHEMOTHERAPY FOR TESTICULAR CANCER - NOT ONLY A BLEOMYCIN EFFECT

被引:38
作者
SLEIJFER, S
VANDERMARK, TW
KOOPS, HS
MULDER, NH
机构
[1] UNIV GRONINGEN HOSP,DIV MED ONCOL,9713 EZ GRONINGEN,NETHERLANDS
[2] UNIV GRONINGEN HOSP,LUNG FUNCT DEPT INTERNAL MED,9713 EZ GRONINGEN,NETHERLANDS
[3] UNIV GRONINGEN HOSP,DEPT SURG ONCOL,9713 EZ GRONINGEN,NETHERLANDS
关键词
BLEOMYCIN; CISPLATIN; PULMONARY FUNCTION; TESTICULAR CANCER;
D O I
10.1038/bjc.1995.24
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study was performed to determine the changes in pulmonary function in patients randomised to receive treatment with four cycles of bleomycin, etoposide and cisplatin (BEP) (27 patients) or with four cycles of etoposide and cisplatin (EP) (27 patients) for disseminated non-seminomatous testicular cancer. This enabled us to establish whether effects other than those due to bleomycin determined the detrimental effects of BEP on lung function assessments. Slow inspiratory vital capacity (VC), the transfer factor of the lungs for carbon monoxide (T-LCO), the diffusing capacity of the alveolo-capillary membrane (D-m), the pulmonary capillary blood volume (V-c) and the transfer factor of the lungs for carbon monoxide per unit alveolar volume (K-CO) were determined before and at 3 week intervals during chemotherapy. Both groups, similar in terms of factors that may influence pulmonary function, showed during therapy a significant decrease in T-LCO compared with the pretreatment value. Only at the end of the therapy was a significant difference in T-LCO between both groups observed. D-m diminished also significantly in both groups during treatment, but differences between both groups were not seen. VC and V-c decreased in patients receiving BEP but remained constant during treatment with EP. It can be concluded that the D-m, K-CO, and the widely used T-LCO are not suitable parameters to monitor specifically pulmonary toxicity induced by bleomycin as part of a multidrug regimen. However, VC and V-c appear to be proper lung function assessments which reflect specifically alterations induced by bleomycin.
引用
收藏
页码:120 / 123
页数:4
相关论文
共 35 条
[11]   ENHANCED PULMONARY TOXICITY IN SMOKERS WITH GERM-CELL CANCER TREATED WITH CIS-PLATINUM, VINBLASTINE AND BLEOMYCIN - A LONG-TERM FOLLOW-UP [J].
HANSEN, SW ;
GROTH, S ;
SORENSEN, PG ;
ROSSING, N ;
RORTH, M .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (04) :733-736
[12]  
JOSELSON R, 1983, HUM PATHOL, V13, P88
[13]  
JULESELYSEE K, 1990, CLIN CHEST MED, V11, P1
[14]   MACROPHAGE PRODUCTION OF TRANSFORMING GROWTH FACTOR-BETA AND FIBROBLAST COLLAGEN-SYNTHESIS IN CHRONIC PULMONARY INFLAMMATION [J].
KHALIL, N ;
BEREZNAY, O ;
SPORN, M ;
GREENBERG, AH .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (03) :727-737
[15]  
KROGH M, 1914, J PHYSIOL-LONDON, V49, P271
[16]   THE IMPORTANCE OF BLEOMYCIN IN COMBINATION CHEMOTHERAPY FOR GOOD-PROGNOSIS GERM-CELL CARCINOMA [J].
LEVI, JA ;
RAGHAVAN, D ;
HARVEY, V ;
THOMPSON, D ;
SANDEMAN, T ;
GILL, G ;
STUARTHARRIS, R ;
SNYDER, R ;
BYRNE, M ;
KERESTES, Z ;
MARGRIE, S .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (07) :1300-1305
[17]  
LUURSEMA PB, 1983, AM REV RESPIR DIS, V128, P880
[18]   AUGMENTATION OF FIBROBLAST PROLIFERATION BY BLEOMYCIN [J].
MOSELEY, PL ;
HEMKEN, C ;
HUNNINGHAKE, GW .
JOURNAL OF CLINICAL INVESTIGATION, 1986, 78 (05) :1150-1154
[19]   A STANDARDIZED BREATH HOLDING TECHNIQUE FOR THE CLINICAL MEASUREMENT OF THE DIFFUSING CAPACITY OF THE LUNG FOR CARBON MONOXIDE [J].
OGILVIE, CM ;
FORSTER, RE ;
BLAKEMORE, WS ;
MORTON, JW .
JOURNAL OF CLINICAL INVESTIGATION, 1957, 36 (01) :1-17
[20]  
OHNUMA T, 1974, CANCER, V33, P1230, DOI 10.1002/1097-0142(197405)33:5<1230::AID-CNCR2820330507>3.0.CO